Oncotarget

VOLUME 10 (2019)

View Archive »

About The Cover

The cover for issue 6 of Oncotarget features Figure 5, "AKT-specific inhibitor MK2206 decreases cell viability, spheroid formation, and migration of SETD2 deficient ccRCC-derived cells," by Terzo, et al.

Table of Contents

News

https://doi.org/10.18632/oncotarget.26545

618-619
PDF  |  How to cite

Editorial

https://doi.org/10.18632/oncotarget.26572

620-621
PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26593

622-623
PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26594

624-625
PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26595

626-628
PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26602

629-630
PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26603

631-632
PDF  |  How to cite

Research Papers

https://doi.org/10.18632/oncotarget.26551

633-646
Abstract  |  PDF  |  Full Text  |  How to cite

https://doi.org/10.18632/oncotarget.26567

647-659
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

https://doi.org/10.18632/oncotarget.26578

660-672
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

https://doi.org/10.18632/oncotarget.26586

673-683
Abstract  |  PDF  |  Full Text  |  How to cite

Corrections

https://doi.org/10.18632/oncotarget.26624

684-684
Correction  |  PDF  |  How to cite

https://doi.org/10.18632/oncotarget.26625

685-685
Correction  |  PDF  |  How to cite


Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC